RecruitingNot Applicable

Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer

Sweden160 participantsStarted 2026-03-19

Plain-language summary

The goal of this prospective observational study is to learn about the short- and long-term effects of treating men over the age of 18 with good prognosis metastatic testicular cancer with either primary retropertioneal lymph node dissection, RPLND, (for low-stage metastastic seminoma) or three doses of chemotherapy for metastastic seminoma or nonseminoma. The main question it aims to answer is: Does primary RPLND lower the risk of side-effects compared to receiving chemotherapy?

Who can participate

Age range18 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients ≥18 years undergoing an open or minimally invasive primary retroperitoneal lymph node dissection (RPLND) due to seminoma stage II A/B (maximum 2 nodes, \<30 mm in any dimension) * Patients undergoing an open or minimally invasive primary RPLND due to a retroperitoneal relapse of seminoma (maximum 2 nodes, \<30 mm in any dimension) * Patients ≥18 years scheduled for 3-4 courses of chemotherapy due to a newly diagnosed good-prognosis metastatic germ cell tumor (nonseminoma or seminoma) Exclusion Criteria: * Previous chemotherapy (including adjuvant chemotherapy at diagnosis) * Previous RPLND * Practical considerations, such as not being able to read and sign informed consent or understand the questionnaires

What they're measuring

HRQOL after treatment as measured by the EORTC QLQ-C30 with the testicular cancer-specific supplement EORTC QLQ-TC26

Timeframe: 2 years

Trial details

NCT IDNCT07498959

SponsorSahlgrenska University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2031-03-25

View on ClinicalTrials.gov More Testicular Cancer trials